Selection of known plasmodium falciparum resistance-mediating polymorphisms by artemether-lumefantrine and amodiaquine-sulfadoxine-pyrimethamine but not dihydroartemisinin-piperaquine in Burkina Faso

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 5, 2010, Pages 1949-1954

  Somé, Anyirékun Fabrice ^a   Séré, Yves Y ^a   Dokomajilar, Christian ^b   Zongo, Issaka ^a   Rouamba, Noël ^a   Greenhouse, Bryan ^b   Ouédraogo, Jean Bosco ^a   Rosenthal, Philip J ^b  

^a Centre National de la Recherche Scientifique et Technologique   (Burkina Faso)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE PLUS FANSIDAR; ANTIMALARIAL AGENT; ARTEMETHER PLUS BENFLUMETOL; CHLOROQUINE; DIHYDROARTEMISININ PLUS PIPERAQUINE; UNCLASSIFIED DRUG;

ANTIMALARIAL DRUG RESISTANCE; ARTICLE; BURKINA FASO; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG TREATMENT FAILURE; GENE SEQUENCE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; PLASMODIUM FALCIPARUM; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TREATMENT DURATION; TREATMENT RESPONSE; WILD TYPE;

AMODIAQUINE; ANTIMALARIALS; ARTEMISININS; BURKINA FASO; DRUG COMBINATIONS; DRUG RESISTANCE, BACTERIAL; ETHANOLAMINES; FLUORENES; GENOTYPE; HUMANS; INFANT; MALARIA, FALCIPARUM; MEMBRANE TRANSPORT PROTEINS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; PLASMODIUM FALCIPARUM; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTOZOAN PROTEINS; PYRIMETHAMINE; QUINOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; SULFADOXINE;

EID: 77951228929     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01413-09     Document Type: Article

References (51)

1. Basco, L. K., and P. Ringwald. 2003. In vitro activities of piperaquine and other 4-aminoquinolines against clinical isolates of Plasmodium falciparum in Cameroon. Antimicrob. Agents Chemother. 47:1391-1394.
2. Bell, D. J., S. K. Nyirongo, M. Mukaka, E. E. Zijlstra, C. V. Plowe, M. E. Molyneux, S. A. Ward, and P. A. Winstanley. 2008. Sulfadoxine-pyrimethamine- based combinations for malaria: a randomised blinded trial to compare efficacy, safety and selection of resistance in Malawi. PLoS One 3:e1578.
3. Davis, T. M., T. Y. Hung, I. K. Sim, H. A. Karunajeewa, and K. F. Ilett. 2005. Piperaquine: a resurgent antimalarial drug. Drugs 65:75-87.
4. Deloron, P., J. Le Bras, J. A. Ramanamirija, and P. Coulanges. 1985. Plasmodium falciparum in Madagascar: in vivo and in vitro sensitivity to seven drugs. Ann. Trop. Med. Parasitol. 79:357-365.
5. Djimdé, A., O. K. Doumbo, J. F. Cortese, K. Kayentao, S. Doumbo, Y. Diourte, A. Dicko, X. Z. Su, T. Nomura, D. A. Fidock, T. E. Wellems, C. V. Plowe, and D. Coulibaly. 2001. A molecular marker for chloroquine-resistant falciparum malaria. N. Engl. J. Med. 344:257-263.
6. Djimde, A. A., B. Fofana, I. Sagara, B. Sidibe, S. Toure, D. Dembele, S. Dama, D. Ouologuem, A. Dicko, and O. K. Doumbo. 2008. Efficacy, safety, and selection of molecular markers of drug resistance by two ACTs in Mali. Am. J. Trop. Med. Hyg. 78:455-461.
7. Dokomajilar, C., Z. M. Lankoande, G. Dorsey, I. Zongo, J. B. Ouedraogo, and P. J. Rosenthal. 2006. Roles of specific Plasmodium falciparum mutations in resistance to amodiaquine and sulfadoxine-pyrimethamine in Burkina Faso. Am. J. Trop. Med. Hyg. 75:162-165.
8. Dokomajilar, C., S. L. Nsobya, B. Greenhouse, P. J. Rosenthal, and G. Dorsey. 2006. Selection of Plasmodium falciparum pfmdr1 alleles following therapy with artemether-lumefantrine in an area of Uganda where malaria is highly endemic. Antimicrob. Agents Chemother. 50:1893-1895.
9. Dorsey, G., C. Dokomajilar, M. Kiggundu, S. G. Staedke, M. R. Kamya, and P. J. Rosenthal. 2004. Principal role of dihydropteroate synthase mutations in mediating resistance to sulfadoxine-pyrimethamine in single-drug and combination therapy of uncomplicated malaria in Uganda. Am. J. Trop. Med. Hyg. 71:758-763.
10. Dorsey, G., M. R. Kamya, A. Singh, and P. J. Rosenthal. 2001. Polymorphisms in the Plasmodium falciparum pfcrt and pfmdr-1 genes and clinical response to chloroquine in Kampala, Uganda. J. Infect. Dis. 183:1417-1420.
11. Dorsey, G., S. Staedke, T. D. Clark, D. Njama-Meya, B. Nzarubara, C. Maiteki-Sebuguzi, C. Dokomajilar, M. R. Kamya, and P. J. Rosenthal. 2007. Combination therapy for uncomplicated falciparum malaria in Ugandan children: a randomized trial. JAMA 297:2210-2219.
12. Duraisingh, M. T., J. Curtis, and D. C. Warhurst. 1998. Plasmodium falciparum: detection of polymorphisms in the dihydrofolate reductase and dihydropteroate synthetase genes by PCR and restriction digestion. Exp. Parasitol. 89:1-8.
13. Duraisingh, M. T., P. Jones, I. Sambou, L. von Seidlein, M. Pinder, and D. C. Warhurst. 2000. The tyrosine-86 allele of the pfmdr1 gene of Plasmodium falciparum is associated with increased sensitivity to the anti-malarials mefloquine and artemisinin. Mol. Biochem. Parasitol. 108:13-23.
14. Fidock, D. A., T. Nomura, A. K. Talley, R. A. Cooper, S. M. Dzekunov, M. T. Ferdig, L. M. Ursos, A. B. Sidhu, B. Naude, K. W. Deitsch, X. Z. Su, J. C. Wootton, P. D. Roepe, and T. E. Wellems. 2000. Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol. Cell 6:861-871.
15. Gasasira, A. F., M. R. Kamya, J. Achan, T. Mebrahtu, J. N. Kalyango, T. Ruel, E. Charlebois, S. G. Staedke, A. Kekitiinwa, P. J. Rosenthal, D. Havlir, and G. Dorsey. 2008. High risk of neutropenia in HIV-infected children following treatment with artesunate plus amodiaquine for uncomplicated malaria in Uganda. Clin. Infect. Dis. 46:985-991.
16. German, P., B. Greenhouse, C. Coates, G. Dorsey, P. J. Rosenthal, E. Charlebois, N. Lindegardh, D. Havlir, and F. T. Aweeka. 2007. Hepatotoxicity due to a drug interaction between amodiaquine plus artesunate and efavirenz. Clin. Infect. Dis. 44:889-891.
17. Greenhouse, B., A. Myrick, C. Dokomajilar, J. M. Woo, E. J. Carlson, P. J. Rosenthal, and G. Dorsey. 2006. Validation of microsatellite markers for use in genotyping polyclonal Plasmodium falciparum infections. Am. J. Trop. Med. Hyg. 75:836-842.
18. Greenwood, B. M., K. Bojang, C. J. Whitty, and T. A. Targett. 2005. Malaria. Lancet 365:1487-1498.
19. Gregson, A., and C. V. Plowe. 2005. Mechanisms of resistance of malaria parasites to antifolates. Pharmacol. Rev. 57:117-145.
20. Happi, C. T., G. O. Gbotosho, O. A. Folarin, O. M. Bolaji, A. Sowunmi, D. E. Kyle, W. Milhous, D. F. Wirth, and A. M. Oduola. 2006. Association between mutations in Plasmodium falciparum chloroquine resistance transporter and P. falciparum multidrug resistance 1 genes and in vivo amodiaquine resistance in P. falciparum malaria-infected children in Nigeria. Am. J. Trop. Med. Hyg. 75:155-161.
21. Hasugian, A. R., H. L. Purba, E. Kenangalem, R. M. Wuwung, E. P. Ebsworth, R. Maristela, P. M. Penttinen, F. Laihad, N. M. Anstey, E. Tjitra, and R. N. Price. 2007. Dihydroartemisinin-piperaquine versus artesunateamodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria. Clin. Infect. Dis. 44:1067-1074.
22. Holmgren, G., J. P. Gil, P. M. Ferreira, M. I. Veiga, C. O. Obonyo, and A. Bjorkman. 2006. Amodiaquine resistant Plasmodium falciparum malaria in vivo is associated with selection of pfcrt 76T and pfmdr1 86Y. Infect. Genet. Evol. 6:309-314.
23. Holmgren, G., J. Hamrin, J. Svard, A. Martensson, J. P. Gil, and A. Bjorkman. 2007. Selection of pfmdr1 mutations after amodiaquine monotherapy and amodiaquine plus artemisinin combination therapy in East Africa. Infect. Genet. Evol. 7:562-569.
24. Humphreys, G. S., I. Merinopoulos, J. Ahmed, C. J. Whitty, T. K. Mutabingwa, C. J. Sutherland, and R. L. Hallett. 2007. Amodiaquine and artemether-lumefantrine select distinct alleles of the Plasmodium falciparum mdr1 gene in Tanzanian children treated for uncomplicated malaria. Anti-microb. Agents Chemother. 51:991-997.
25. Hung, T. Y., T. M. Davis, K. F. Ilett, H. Karunajeewa, S. Hewitt, M. B. Denis, C. Lim, and D. Socheat. 2004. Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malaria. Br. J. Clin. Pharmacol. 57:253-262.
26. Kamya, M. R., A. Yeka, H. Bukirwa, M. Lugemwa, J. B. Rwakimari, S. G. Staedke, A. O. Talisuna, B. Greenhouse, F. Nosten, P. J. Rosenthal, F. Wabwire-Mangen, and G. Dorsey. 2007. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment of malaria: a randomized trial. PLoS Clin. Trials 2:e20.
27. Karema, C., C. I. Fanello, C. van Overmeir, J. P. van Geertruyden, W. van Doren, D. Ngamije, and U. D'Alessandro. 2006. Safety and efficacy of dihydroartemisinin/ piperaquine (Artekin) for the treatment of uncomplicated Plasmodium falciparum malaria in Rwandan children. Trans. R. Soc. Trop. Med. Hyg. 100:1105-1111.
28. Maiteki-Sebuguzi, C., P. Jagannathan, V. M. Yau, T. D. Clark, D. Njama-Meya, B. Nzarubara, A. O. Talisuna, M. R. Kamya, P. J. Rosenthal, G. Dorsey, and S. G. Staedke. 2008. Safety and tolerability of combination antimalarial therapies for uncomplicated falciparum malaria in Ugandan children. Malar. J. 7:106.
29. Mårtensson, A., J. Stromberg, C. Sisowath, M. I. Msellem, J. P. Gil, S. M. Montgomery, P. Olliaro, A. S. Ali, and A. Bjorkman. 2005. Efficacy of artesunate plus amodiaquine versus that of artemether-lumefantrine for the treatment of uncomplicated childhood Plasmodium falciparum malaria in Zanzibar, Tanzania. Clin. Infect. Dis. 41:1079-1086.
30. Muangnoicharoen, S., D. J. Johnson, S. Looareesuwan, S. Krudsood, and S. A. Ward. 2009. Role of known molecular markers of resistance in the antimalarial potency of piperaquine and dihydroartemisinin in vitro. Anti-microb. Agents Chemother. 53:1362-1366.
31. Mutabingwa, T. K., D. Anthony, A. Heller, R. Hallett, J. Ahmed, C. Drakeley, B. M. Greenwood, and C. J. Whitty. 2005. Amodiaquine alone, amodiaquine+ sulfadoxine-pyrimethamine, amodiaquine+artesunate, and artemether-lumefantrine for outpatient treatment of malaria in Tanzanian children: a four-arm randomised effectiveness trial. Lancet 365:1474-1480.
32. Mwai, L., S. M. Kiara, A. Abdirahman, L. Pole, A. Rippert, A. Diriye, P. Bull, K. Marsh, S. Borrmann, and A. Nzila. 2009. In vitro activity of piperaquine, lumefantrine and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in Pfcrt and Pfmdr1. Antimicrob. Agents Chemother.
33. Nguyen, T. C., N. Q. Nguyen, X. T. Nguyen, D. Bui, T. Travers, and M. D. Edstein. 2008. Pharmacokinetics of the antimalarial drug piperaquine in healthy Vietnamese subjects. Am. J. Trop. Med. Hyg. 79:620-623.
34. Nsobya, S. L., C. Dokomajilar, M. Joloba, G. Dorsey, and P. J. Rosenthal. 2007. Resistance-mediating Plasmodium falciparum pfcrt and pfmdr1 alleles after treatment with artesunate-amodiaquine in Uganda. Antimicrob. Agents Chemother. 51:3023-3025.
35. Nsobya, S. L., M. Kiggundu, S. Nanyunja, M. Joloba, B. Greenhouse, and P. J. Rosenthal. 2010. In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda. Antimicrob. Agents Chemother. 54:1200-1206.
36. Ochong, E. O., I. V. van den Broek, K. Keus, and A. Nzila. 2003. Short report: association between chloroquine and amodiaquine resistance and allelic variation in the Plasmodium falciparum multiple drug resistance 1 gene and the chloroquine resistance transporter gene in isolates from the upper Nile in southern Sudan. Am. J. Trop. Med. Hyg. 69:184-187.
37. Orrell, C., F. Little, P. Smith, P. Folb, W. Taylor, P. Olliaro, and K. I. Barnes. 2008. Pharmacokinetics and tolerability of artesunate and amodiaquine alone and in combination in healthy volunteers. Eur. J. Clin. Pharmacol. 64:683-690.
38. Pearce, R. J., H. Pota, M. S. Evehe, E.-H. Ba, G. Mombo-Ngoma, A. L. Malisa, R. Ord, W. Inojosa, A. Matondo, D. A. Diallo, W. Mbacham, I. V. van den Broek, T. D. Swarthout, A. Getachew, S. Dejene, M. P. Grobusch, F. Njie, S. Dunyo, M. Kweku, S. Owusu-Agyei, D. Chandramohan, M. Bonnet, J. P. Guthmann, S. Clarke, K. I. Barnes, E. Streat, S. T. Katokele, P. Uusiku, C. O. Agboghoroma, O. Y. Elegba, B. Cisse, I. E. A-Elbasit, H. A. Giha, S. P. Kachur, C. Lynch, J. B. Rwakimari, P. Chanda, M. Hawela, B. Sharp, I. Naidoo, and C. Roper. 2009. Multiple origins and regional dispersal of resistant dhps in African Plasmodium falciparum malaria. PLoS Med. 6:e1000055.
39. Ratcliff, A., H. Siswantoro, E. Kenangalem, R. Maristela, R. M. Wuwung, F. Laihad, E. P. Ebsworth, N. M. Anstey, E. Tjitra, and R. N. Price. 2007. Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison. Lancet 369:757-765.
40. Reed, M. B., K. J. Saliba, S. R. Caruana, K. Kirk, and A. F. Cowman. 2000. Pgh1 modulates sensitivity and resistance to multiple antimalarials in Plasmodium falciparum. Nature 403:906-909.
41. Sisowath, C., J. Stromberg, A. Martensson, M. Msellem, C. Obondo, A. Bjorkman, and J. P. Gil. 2005. In vivo selection of Plasmodium falciparum pfmdr1 86N coding alleles by artemether-lumefantrine (Coartem). J. Infect. Dis. 191:1014-1017.
42. Smithuis, F., M. K. Kyaw, O. Phe, K. Z. Aye, L. Htet, M. Barends, N. Lindegardh, T. Singtoroj, E. Ashley, S. Lwin, K. Stepniewska, and N. J. White. 2006. Efficacy and effectiveness of dihydroartemisinin-piperaquine versus artesunate-mefloquine in falciparum malaria: an open-label randomised comparison. Lancet 367:2075-2085.
43. Stepniewska, K., and N. J. White. 2008. Pharmacokinetic determinants of the window of selection for antimalarial drug resistance. Antimicrob. Agents Chemother. 52:1589-1596.
44. Sutherland, C. J., A. Alloueche, J. Curtis, C. J. Drakeley, R. Ord, M. Duraisingh, B. M. Greenwood, M. Pinder, D. Warhurst, and G. A. Targett. 2002. Gambian children successfully treated with chloroquine can harbor and transmit Plasmodium falciparum gametocytes carrying resistance genes. Am. J. Trop. Med. Hyg. 67:578-585.
45. Tarning, J., E. A. Ashley, N. Lindegardh, K. Stepniewska, L. Phaiphun, N. P. Day, R. McGready, M. Ashton, F. Nosten, and N. J. White. 2008. Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand. Antimicrob. Agents Chemother. 52:1052-1061.
46. Valderramos, S. G., and D. A. Fidock. 2006. Transporters involved in resistance to antimalarial drugs. Trends Pharmacol. Sci. 27:594-601.
47. White, N. J. 2008. Qinghaosu (artemisinin): the price of success. Science 320:330-334.
48. Woodrow, C. J., and S. Krishna. 2006. Antimalarial drugs: recent advances in molecular determinants of resistance and their clinical significance. Cell. Mol. Life Sci. 63:1586-1596.
49. Yeka, A., G. Dorsey, M. R. Kamya, A. Talisuna, M. Lugemwa, J. B. Rwakimari, S. G. Staedke, P. J. Rosenthal, F. Wabwire-Mangen, and H. Bukirwa. 2008. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda. PLoS One 3:e2390.
50. Zongo, I., G. Dorsey, N. Rouamba, C. Dokomajilar, Y. Sere, P. J. Rosenthal, and J. B. Ouedraogo. 2007. Randomized comparison of amodiaquine plus sulfadoxine-pyrimethamine, artemether-lumefantrine, and dihydroartemisinin- piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Burkina Faso. Clin. Infect. Dis. 45:1453-1461.
51. Zongo, I., G. Dorsey, N. Rouamba, H. Tinto, C. Dokomajilar, R. T. Guiguemde, P. J. Rosenthal, and J. B. Ouedraogo. 2007. Artemether-lumefantrine versus amodiaquine plus sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Burkina Faso: a randomised non-inferiority trial. Lancet 369:491-498.